The inclusion of Thailand and Cambodia is part of Hyphens Pharma’s strengthening of its footprint across Southeast Asia, the release reads.
Hyphens Pharma International’s subsidiary has extended its partnership with Medac Gesellschaft für klinische Spezialpräparate (medac) to include Thailand and Cambodia for the commercialization of an autoinjector pen.
This builds on the existing agreement signed in March 2025 which granted Hyphens Pharma exclusive rights to register and commercialise the Metoject® subcutaneous autoinjector pen in Singapore, Malaysia, the Philippines, and Vietnam.
